Full name :
First name :
Mail :
Zip Code :
City :
Country :
Email :
Phone :
Fax :
Website :
Directory :
| Title : Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial - Maki-Petaja_2021_Hypertension__HYPERTENSIONAHA12016454 |
| Author(s) : Maki-Petaja KM , McGeoch A , Yang LL , Hubsch A , McEniery CM , Meyer PAR , Mir F , Gajendragadkar P , Ramenatte N , Anandappa G , Santos Franco S , Bond SJ , Schonlieb CB , Boink Y , Brune C , Wilkinson IB , Jodrell DI , Cheriyan J |
| Ref : Hypertension , :HYPERTENSIONAHA12016454 , 2021 |
| Abstract : Maki-Petaja_2021_Hypertension__HYPERTENSIONAHA12016454 |
| ESTHER : Maki-Petaja_2021_Hypertension__HYPERTENSIONAHA12016454 |
| PubMedSearch : Maki-Petaja_2021_Hypertension__HYPERTENSIONAHA12016454 |
| PubMedID: 33775123 |
| Title : Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers - Yang_2017_Chest_151_555 |
| Author(s) : Yang L , Cheriyan J , Gutterman DD , Mayer RJ , Ament Z , Griffin JL , Lazaar AL , Newby DE , Tal-Singer R , Wilkinson IB |
| Ref : Chest , 151 :555 , 2017 |
| Abstract : Yang_2017_Chest_151_555 |
| ESTHER : Yang_2017_Chest_151_555 |
| PubMedSearch : Yang_2017_Chest_151_555 |
| PubMedID: 27884766 |
| Title : Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor - Lazaar_2016_Br.J.Clin.Pharmacol_81_971 |
| Author(s) : Lazaar AL , Yang L , Boardley RL , Goyal NS , Robertson J , Baldwin SJ , Newby DE , Wilkinson IB , Tal-Singer R , Mayer RJ , Cheriyan J |
| Ref : British Journal of Clinical Pharmacology , 81 :971 , 2016 |
| Abstract : Lazaar_2016_Br.J.Clin.Pharmacol_81_971 |
| ESTHER : Lazaar_2016_Br.J.Clin.Pharmacol_81_971 |
| PubMedSearch : Lazaar_2016_Br.J.Clin.Pharmacol_81_971 |
| PubMedID: 26620151 |